Surface Oncology Inc. (NASDAQ:SURF) shares traded 0.93% higher at $1.08 on Wall Street last session.
In accordance with the data, 5 analysts cover Surface Oncology Inc. (NASDAQ:SURF). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $1.00, we find $3.08. Given the previous closing price of $1.07, this indicates a potential upside of 187.85 percent. SURF stock price is now 14.49% away from the 50-day moving average and 31.37% away from the 200-day moving average. The market capitalization of the company currently stands at $65.10M.
It has been rated a hold by 4 analysts and a buy by 1. Brokers who have rated the stock have averaged $3.29 as their price target over the next twelve months.
With the price target of $17, BTIG Research recently initiated with Buy rating for Surface Oncology Inc. (NASDAQ: SURF).
In other news, ROSS ROBERT W., Chief Executive Officer sold 16,713 shares of the company’s stock on Aug 01. The stock was sold for $15,710 at an average price of $0.94. Upon completion of the transaction, the Chief Executive Officer now directly owns 83,193 shares in the company, valued at $89848.44. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 01, Chief Financial Officer FEES JESSICA sold 9,434 shares of the business’s stock. A total of $8,868 was realized by selling the stock at an average price of $0.94. This leaves the insider owning 101,915 shares of the company worth $0.11 million. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SURF stock. A new stake in Surface Oncology Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $5,281,000. YAKIRA CAPITAL MANAGEMENT, INC. invested $849,000 in shares of SURF during the first quarter. In the first quarter, BLACK MAPLE CAPITAL MANAGEMENT LP acquired a new stake in Surface Oncology Inc. valued at approximately $288,000. BOOTHBAY FUND MANAGEMENT, LLC acquired a new stake in SURF for approximately $49,000. CHARLES SCHWAB INVESTMENT MANAGEMENT INC purchased a new stake in SURF valued at around $48,000 in the second quarter. In total, there are 92 active investors with 53.50% ownership of the company’s stock.
Surface Oncology Inc. (NASDAQ: SURF) opened at $1.0900 on Friday. During the past 12 months, Surface Oncology Inc. has had a low of $0.56 and a high of $1.43. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.60, and a quick ratio of 3.60. The fifty day moving average price for SURF is $0.9477 and a two-hundred day moving average price translates $0.8218 for the stock.
The latest earnings results from Surface Oncology Inc. (NASDAQ: SURF) was released for Jun, 2023.
Surface Oncology Inc.(SURF) Company Profile
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
